Bertis
BERTIS is a company specializing in proteomics-based precision medicine technology, focusing on early disease diagnosis and personalized treatment. They develop and commercialize advanced proteomics analysis solutions, including blood-based diagnostic tests for cancer detection and other health conditions. Their mission is to unravel the proteome for the next era of precision medicine, aiming to improve healthcare outcomes through innovative proteomics technologies.
Industries
Nr. of Employees
small (1-50)
Products
Proteomics-based blood test for early breast cancer detection
A blood-based diagnostic assay that quantifies multiple protein biomarkers and applies an algorithmic model to support early-stage breast cancer screening.
Proteomics data analysis platform
An integrated platform supporting protein data analysis, biomarker discovery, and downstream product and service development workflows.
Proteomics-based blood test for early breast cancer detection
A blood-based diagnostic assay that quantifies multiple protein biomarkers and applies an algorithmic model to support early-stage breast cancer screening.
Proteomics data analysis platform
An integrated platform supporting protein data analysis, biomarker discovery, and downstream product and service development workflows.
Services
Laboratory-based mass spectrometry proteomics combined with bioinformatics consulting to support research, drug discovery, and translational projects.
Provision and distribution of proteomics-based clinical testing through partner clinical laboratories and regional laboratory networks.
Laboratory-based mass spectrometry proteomics combined with bioinformatics consulting to support research, drug discovery, and translational projects.
Provision and distribution of proteomics-based clinical testing through partner clinical laboratories and regional laboratory networks.
Expertise Areas
- Proteomics-based diagnostics
- Pan-omics analysis and bioinformatics
- Biomarker discovery and validation
- Clinical diagnostic assay development
Key Technologies
- Mass spectrometry-based proteomics
- Pan-omics profiling
- Proteome and phosphoproteome analysis
- Bioinformatics pipelines for proteomics
News & Updates
Bertis announced a strategic partnership with Innoquest Diagnostics to establish local testing infrastructure for proteomics-based blood tests for early breast cancer detection in Southeast Asia, with plans for expansion into other markets.
Bertis announced its participation in BIO KOREA 2025, showcasing its omics analysis service PASS, and sharing recent research achievements and project outcomes.
Bertis launched MASTOCHECK® in Thailand and the Philippines through a partnership with LifeStrands, aiming for rapid adoption supported by local medical professionals.
Bertis signed an MOU with COSMAX to collaborate on skin proteomics analysis, biomarker panel development, and personalized skin aging care.
Bertis appointed Dr. David Berry, a global authority in innovation and sustainable management, as a member of its Scientific Advisory Board to support its global expansion.
A study conducted by the Center for Synaptic Brain Dysfunctions at the Institute for Basic Science (IBS) investigated the impact of DYRK1A gene deficiency on neurodevelopmental disorders, supported by Bertis PASS.
Bertis announced a strategic partnership with Innoquest Diagnostics to establish local testing infrastructure for proteomics-based blood tests for early breast cancer detection in Southeast Asia, with plans for expansion into other markets.
Bertis announced its participation in BIO KOREA 2025, showcasing its omics analysis service PASS, and sharing recent research achievements and project outcomes.
Bertis launched MASTOCHECK® in Thailand and the Philippines through a partnership with LifeStrands, aiming for rapid adoption supported by local medical professionals.
Bertis signed an MOU with COSMAX to collaborate on skin proteomics analysis, biomarker panel development, and personalized skin aging care.
Bertis appointed Dr. David Berry, a global authority in innovation and sustainable management, as a member of its Scientific Advisory Board to support its global expansion.
A study conducted by the Center for Synaptic Brain Dysfunctions at the Institute for Basic Science (IBS) investigated the impact of DYRK1A gene deficiency on neurodevelopmental disorders, supported by Bertis PASS.